Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-07-10
2004-03-23
Chang, Ceila (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06710043
ABSTRACT:
TECHNICAL FIELD
This invention relates to new amide compounds and pharmaceutically acceptable salts thereof which are useful as a medicament.
BACKGROUND ART
Some aminopiperazine derivatives have been known as useful anti-amnesia or anti-dementia agents, for example, in PCT International Publication Nos. WO 91/01979 and WO 98/35951.
DISCLOSURE OF INVENTION
This invention relates to new amide compounds and pharmaceutically acceptable salts thereof.
More particularly, it relates to new amide compounds and pharmaceutically acceptable salts thereof which have the potentiation of the cholinergic activity, to processes for the preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the treatment and/or prevention of disorders in the central nervous system for mammals, and more particularly to method for the treatment and/or prevention of amnesia, dementia (e.g., senile dementia, Alzheimer's dementia, dementia associated with various diseases such as cerebral vascular dementia, cerebral post-traumatic dementia, dementia due to brain tumor, dementia due to chronic subdural hematoma, dementia due to normal pressure hydrocephalus, post-meningitis dementia, Parkinson's disease type dementia, etc.), and the like. Additionally, the object compound is expected to be useful as therapeutical and/or preventive agents for schizophrenia, depression, stroke, head injury, nicotine withdrawal, spinal cord injury, anxiety, pollakiuria, incontinence of urine, myotonic dystrophy, attention deficit hyperactivity disorder, excessive daytime sleepiness (narcolepsy), Parkinson's disease or autism.
One object of this invention is to provide new and useful amide compounds and pharmaceutically acceptable salts thereof which possess the potentiation of the cholinergic activity.
Another object of this invention is to provide processes for preparation of said amide compounds and salts thereof.
A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said amide compounds and pharmaceutically acceptable salt thereof.
Still further object of this invention is to provide a therapeutic method for the treatment and/or prevention of aforesaid diseases in mammals, using said amide compounds and pharmaceutically acceptable salts thereof.
The amide compounds of this invention are new and can be represented by the following general formula [I]:
wherein R
1
is acyl,
R
2
is lower alkyl, lower alkoxy, lower alkylamino, lower alkenyl, lower alkenyloxy, lower alkenylamino, lower alkynyl, lower alkynyloxy, lower alkynylamino, cyclo(lower)alkyl, cyclo(lower)alkyloxy, cyclo(lower)alkylamino, aryl, aryloxy, arylamino, a heterocyclic group or amino substituted with a heterocyclic group, each of which may be substituted with suitable substituent(s); or acyl;
A is a single bond,
or —SO
2
—,
E is lower alkylene optionally substituted with suitable substituent(s),
X is CH or N,
Y is a single bond, lower alkylene or
wherein R
5
is hydrogen, lower alkyl, substituted-lower alkyl, an N-protective group, aryl, acyl or a heterocyclic group),
Q is —CH
2
—,
—SO
2
— or —N═CH—, and
R
3
and R
4
are each hydrogen or lower alkyl, or are taken together to form lower alkylene optionally condensed with a cyclic hydrocarbon or a heterocyclic ring,
provided that when X is N,
then 1) Y is a single bond, and
Q is —CH
2
—,
or —SO
2
—, or
2) Y is lower alkylene,
and pharmaceutically acceptable salts thereof. The object compound [I] or its salt can be prepared by processes as illustrated in the following reaction schemes.
wherein R
1
, R
2
, R
3
, R
4
, A, E, Q, X and Y are each as defined above,
Q
a
is
or —SO
2
—,
R
6
is aryl which may be substituted with suitable substituent(s), or pyridyl,
R
7
is lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, aryl or a heterocyclic group, each of which may be substituted with suitable substituent(s),
R
a
5
is an N-protective group,
R
a
2
is lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, aryl or a heterocyclic group, each of which may be substituted with suitable substituent(s),
Q
b
is —CH
2
—,
or —SO
2
—,
Z
a
is an acid residue,
Q
c
is
R
b
5
is lower alkyl,
Z
b
is an acid residue,
Z
c
is an acid residue, and
Y
a
is lower alkylene.
In the above and subsequent description of the present specification, suitable examples of the various definitions to be included within the scope of the invention are explained in detail in the following.
The term “lower” is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided.
The lower moiety in the term “lower alkenyl”, “lower alkenyloxy”, “lower alkenylamino”, “lower alkynyl”, “lower alkynyloxy” and “lower alkynylamino” is intended to mean a group having 2 to 6 carbon atoms.
The lower moiety in the terms “cyclo(lower)alkyl”, “cyclo(lower)alkyloxy” and “cyclo(lower)alkylamino” is intended to mean a group having 3 to 6 carbon atoms.
Suitable “lower alkyl” and lower alkyl moiety in the terms “substituted-lower alkyl”, “ar(lower)alkyl”, “halo(lower)alkyl”, “lower alkylamino”, “lower alkylsilyl”, “lower alkylthio” and “lower alkylsulfonyl” may be a straight or branched C
1
-C
6
alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, ethylpropyl, hexyl or the like, in which preferable one is methyl.
Suitable “lower alkenyl” and lower alkenyl moiety in the terms “lower alkenyloxy” and “lower alkenylamino” may be a straight or branched C
2
-C
6
alkenyl such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, isopropenyl, butadienyl, pentadienyl, hexadienyl or the like, in which preferable one is ethenyl, propentyl or butadienyl.
Suitable “lower alkynyl” and lower alkynyl moiety in the terms “lower alkynyloxy” and “lower alkynylamino” may be a straight or branched C
2
-C
6
alkynyl such as ethynyl, propargyl, butynyl or the like, in which preferable one is ethynyl.
Suitable “cyclo(lower)alkyl” and cyclo(lower)alkyl moiety in the terms “cyclo(lower)alkyloxy” and “cyclo(lower)alkylamino” may be cyclo(C
3
-C
6
)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in which preferable one is cyclopropyl.
Suitable “aryl” and aryl or ar moiety in the terms “ar(lower)alkoxy”, “aryloxy”, “arylamino”, “arylsulfonyl”, “aroyl” and “ar(lower)alkyl” may be phenyl, naphthyl, phenyl substituted with lower alkyl [e.g. tolyl, xylyl, mesityl, cumenyl, di(tert-butyl)phenyl, etc.] and the like, in which preferable one is phenyl or tolyl.
Suitable “ar(lower)alkyl” may be benzyl, phenethyl, phenylpropyl, benzhydryl, trityl and the like, in which preferable one is benzyl.
Suitable “lower alkylene” and lower alkylene moiety in the term “lower alkylenedioxy” may be a straight or branched C
1
-C
6
alkylene such as methylene, ethylene, trimethylene, propylene, tetramethylene, pentamethylene, hexamethylene, ethylethylene or the like, in which preferable one is methylene, ethylene or trimethylene.
Suitable “lower alkoxy” and lower alkoxy moiety in the terms “ar(lower)alkoxy” and “halo(lower)alkoxy” may be a straight or branched C
1
-C
6
alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, methylpropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy or the like, in which preferable one is methoxy or tert-butoxy.
Suitable “ar(lower)alkoxy” may be benzyloxy, phenethyloxy, phenylpropoxy, benzhydryloxy, trityloxy and the like.
Suitable “halogen” and halo moiety in the term “halo(lower)alkyl” may be fluorine, chlorine, bromine and iodine, in which preferable one is fluorine, chlorine or iodine.
Suitable “halo(lower)alkyl” may be lower alkyl substituted with one or more halogens such as chloromethyl, dichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, pentachloroethyl or the like, in which preferable one is trifluoromethyl.
Suitable “halo(lower)alkoxy” may be lower alkoxy substituted with one or more halogens such as chloromethoxy, dichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, pentachloromethoxy or t
Aoki Satoshi
Yamada Akira
Chang Ceila
Fujisawa Pharmaceutical Co. Ltd.
LandOfFree
Amide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3232143